Moderna Inc. published a document detailing the safety, tolerability, and immunogenicity of the mRNA-1345 RSV vaccine in solid organ transplant recipients. The document includes information on a Phase 3, open-label study with adult participants who have received kidney, lung, or liver transplants. Study design, dosing regimen, and follow-up details are provided. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.